{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:51:47Z","timestamp":1776707507599,"version":"3.51.2"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72074142"],"award-info":[{"award-number":["72074142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10620-025-09419-8","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:48:49Z","timestamp":1758980929000},"page":"919-932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness of Risk-Score-Based Surveillance Strategies for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B"],"prefix":"10.1007","volume":"71","author":[{"given":"Ying","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaijie","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"9419_CR1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","volume":"8","author":"Polaris Observatory Collaborators","year":"2023","unstructured":"Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol 2023;8:879\u2013907. https:\/\/doi.org\/10.1016\/S2468-1253(23)00197-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9419_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3201\/eid2305.161477","volume":"23","author":"F Cui","year":"2017","unstructured":"Cui F, Shen L, Li L et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis 2017;23:765\u2013772. https:\/\/doi.org\/10.3201\/eid2305.161477.","journal-title":"Emerg Infect Dis"},{"key":"9419_CR3","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1186\/s12889-024-18918-8","volume":"24","author":"C Freeland","year":"2024","unstructured":"Freeland C, Qureshi A, Wallace J et al. Hepatitis B discrimination: global responses requiring global data. BMC Public Health 2024;24:1575. https:\/\/doi.org\/10.1186\/s12889-024-18918-8.","journal-title":"BMC Public Health"},{"key":"9419_CR4","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S0140-6736(08)61364-1","volume":"372","author":"S Tang","year":"2008","unstructured":"Tang S, Meng Q, Chen L, Bekedam H, Evans T, Whitehead M. Tackling the challenges to health equity in China. Lancet 2008;372:1493\u20131501. https:\/\/doi.org\/10.1016\/S0140-6736(08)61364-1.","journal-title":"Lancet"},{"key":"9419_CR5","doi-asserted-by":"publisher","unstructured":"Molecular mechanism network pharmacology and bioinformatics research of Qingrejiedu decoction in treatment of liver and gallbladder neoplasms. Pak Vet J. 2023. https:\/\/doi.org\/10.29261\/pakvetj\/2023.045.","DOI":"10.29261\/pakvetj\/2023.045"},{"key":"9419_CR6","doi-asserted-by":"publisher","unstructured":"Reviewing advances in understanding and targeting the MAPK signaling pathway in hepatocellular carcinoma progression and therapeutics. Agrobiol Rec 2024;15:103\u201316. https:\/\/doi.org\/10.47278\/journal.abr\/2024.004.","DOI":"10.47278\/journal.abr\/2024.004"},{"key":"9419_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","volume":"48","author":"G Fattovich","year":"2008","unstructured":"Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335\u2013352. https:\/\/doi.org\/10.1016\/j.jhep.2007.11.011.","journal-title":"J Hepatol"},{"key":"9419_CR8","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204\u20131222. https:\/\/doi.org\/10.1016\/S0140-6736(20)30925-9.","journal-title":"Lancet"},{"key":"9419_CR9","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.21037\/atm-22-5676","volume":"10","author":"M Yan","year":"2022","unstructured":"Yan M, Wu B. Hepatitis B and C mortality from 1990 to 2019 in China: a Bayesian age-period-cohort analysis. Ann Transl Med 2022;10:1384. https:\/\/doi.org\/10.21037\/atm-22-5676.","journal-title":"Ann Transl Med"},{"key":"9419_CR10","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.12998\/wjcc.v9.i14.3238","volume":"9","author":"J Guo","year":"2021","unstructured":"Guo J, Gao X-S. Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients. World J Clin Cases 2021;9:3238\u20133251. https:\/\/doi.org\/10.12998\/wjcc.v9.i14.3238.","journal-title":"World J Clin Cases"},{"key":"9419_CR11","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","volume":"18","author":"AM Moon","year":"2020","unstructured":"Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol 2020;18:2650\u20132666. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.060.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9419_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","journal-title":"Nat Rev Dis Primers"},{"key":"9419_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology 2018;68:723\u2013750. https:\/\/doi.org\/10.1002\/hep.29913.","journal-title":"Hepatology"},{"key":"9419_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019.","journal-title":"J Hepatol"},{"key":"9419_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","volume":"130","author":"B-H Zhang","year":"2004","unstructured":"Zhang B-H, Yang B-H, Tang Z-Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417\u2013422. https:\/\/doi.org\/10.1007\/s00432-004-0552-0.","journal-title":"J Cancer Res Clin Oncol"},{"key":"9419_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","volume":"77","author":"AG Singal","year":"2022","unstructured":"Singal AG, Zhang E, Narasimman M et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol 2022;77:128\u2013139. https:\/\/doi.org\/10.1016\/j.jhep.2022.01.023.","journal-title":"J Hepatol"},{"key":"9419_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00618-8","author":"H Zeng","year":"2023","unstructured":"Zeng H, Cao M, Xia C et al. Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study. Nat Cancer. 2023. https:\/\/doi.org\/10.1038\/s43018-023-00618-8.","journal-title":"Nat Cancer"},{"key":"9419_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3390\/v13071333","volume":"13","author":"J Lok","year":"2021","unstructured":"Lok J, Agarwal K. Screening for hepatocellular carcinoma in chronic hepatitis B: an update. Viruses 2021;13:1333. https:\/\/doi.org\/10.3390\/v13071333.","journal-title":"Viruses"},{"key":"9419_CR19","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s11606-011-1952-x","volume":"27","author":"AG Singal","year":"2012","unstructured":"Singal AG, Yopp A, Skinner CS, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012;27:861\u2013867. https:\/\/doi.org\/10.1007\/s11606-011-1952-x.","journal-title":"J Gen Intern Med"},{"key":"9419_CR20","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1111\/liv.12764","volume":"35","author":"P Edenvik","year":"2015","unstructured":"Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, St\u00e5l P. Application of hepatocellular carcinoma surveillance in a European setting: what can we learn from clinical practice? Liver Int 2015;35:1862\u20131871. https:\/\/doi.org\/10.1111\/liv.12764.","journal-title":"Liver Int"},{"key":"9419_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/hepr.12714","volume":"47","author":"A Hirata","year":"2017","unstructured":"Hirata A, Hirata T, Takahashi Y, Nakayama T. Surveillance rates for hepatocellular carcinoma among patients with cirrhosis, chronic hepatitis B, and chronic hepatitis C based on Japanese claims database. Hepatol Res 2017;47:283\u2013292. https:\/\/doi.org\/10.1111\/hepr.12714.","journal-title":"Hepatol Res"},{"key":"9419_CR22","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","volume":"164","author":"MR Toh","year":"2023","unstructured":"Toh MR, Wong EYT, Wong SH et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology 2023;164:766\u2013782. https:\/\/doi.org\/10.1053\/j.gastro.2023.01.033.","journal-title":"Gastroenterology"},{"key":"9419_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12985-023-02145-5","volume":"20","author":"X Xu","year":"2023","unstructured":"Xu X, Jiang L, Zeng Y, Pan L, Lou Z, Ruan B. HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis. Virol J 2023;20:180. https:\/\/doi.org\/10.1186\/s12985-023-02145-5.","journal-title":"Virol J"},{"key":"9419_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","volume":"24","author":"X Yue","year":"2021","unstructured":"Yue X, Li Y, Wu J, Guo JJ. Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China. Value Health Regional Iss 2021;24:1\u20135. https:\/\/doi.org\/10.1016\/j.vhri.2020.07.580.","journal-title":"Value Health Regional Iss"},{"key":"9419_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health 2022;25:10\u201331. https:\/\/doi.org\/10.1016\/j.jval.2021.10.008.","journal-title":"Value Health"},{"key":"9419_CR26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jhep.2022.12.007","volume":"78","author":"W-M Choi","year":"2023","unstructured":"Choi W-M, Yip TC-F, Wong GL-H et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs entecavir-based regimens: Individual patient data meta-analysis. J Hepatol 2023;78:534\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2022.12.007.","journal-title":"J Hepatol"},{"key":"9419_CR27","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.3748\/wjg.v24.i40.4606","volume":"24","author":"Y-C Ju","year":"2018","unstructured":"Ju Y-C, Jun D-W, Choi J, Saeed WK, Lee H-Y, Oh H-W. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis. World J Gastroenterol 2018;24:4606\u20134614. https:\/\/doi.org\/10.3748\/wjg.v24.i40.4606.","journal-title":"World J Gastroenterol"},{"key":"9419_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jhep.2022.01.027","volume":"77","author":"PP Mueller","year":"2022","unstructured":"Mueller PP, Chen Q, Ayer T et al. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. J Hepatol 2022;77:55\u201362. https:\/\/doi.org\/10.1016\/j.jhep.2022.01.027.","journal-title":"J Hepatol"},{"key":"9419_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3350\/cmh.2015.21.3.279","volume":"21","author":"C An","year":"2015","unstructured":"An C, Choi YA, Choi D et al. Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. Clin Mol Hepatol 2015;21:279\u2013286. https:\/\/doi.org\/10.3350\/cmh.2015.21.3.279.","journal-title":"Clin Mol Hepatol"},{"key":"9419_CR30","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.surg.2023.06.022","volume":"174","author":"T Yoh","year":"2023","unstructured":"Yoh T, Ishii T, Ogiso S et al. Long-term outcomes and salvageability in patients undergoing liver resection for intermediate- and advanced-stage hepatocellular carcinoma. Surgery 2023;174:858\u2013864. https:\/\/doi.org\/10.1016\/j.surg.2023.06.022.","journal-title":"Surgery"},{"key":"9419_CR31","doi-asserted-by":"publisher","first-page":"544","DOI":"10.4240\/wjgs.v15.i4.544","volume":"15","author":"D Wang","year":"2023","unstructured":"Wang D, Xiao M, Wan Z-M, Lin X, Li Q-Y, Zheng S-S. Surgical treatment for recurrent hepatocellular carcinoma: current status and challenges. World J Gastrointest Surg 2023;15:544\u2013552. https:\/\/doi.org\/10.4240\/wjgs.v15.i4.544.","journal-title":"World J Gastrointest Surg"},{"key":"9419_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4254\/wjh.v10.i6.433","volume":"10","author":"YX Koh","year":"2018","unstructured":"Koh YX, Tan HL, Lye WK et al. Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: a critical appraisal of the evidence. World J Hepatol 2018;10:433\u2013447. https:\/\/doi.org\/10.4254\/wjh.v10.i6.433.","journal-title":"World J Hepatol"},{"key":"9419_CR33","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/hepr.13811","volume":"52","author":"Y-J Xiang","year":"2022","unstructured":"Xiang Y-J, Wang K, Yu H-M et al. Hazard rate for postoperative recurrence in patients with hepatocellular carcinoma at Barcelona Clinic Liver Cancer stage 0 or A1: a multicenter observational study. Hepatol Res 2022;52:947\u2013956. https:\/\/doi.org\/10.1111\/hepr.13811.","journal-title":"Hepatol Res"},{"key":"9419_CR34","doi-asserted-by":"publisher","first-page":"677920","DOI":"10.3389\/fmed.2021.677920","volume":"8","author":"H Gui","year":"2021","unstructured":"Gui H, Huang Y, Zhao G et al. External validation of aMAP hepatocellular carcinoma risk score in patients with chronic hepatitis B-related cirrhosis receiving ETV or TDF therapy. Front Med (Lausanne) 2021;8:677920. https:\/\/doi.org\/10.3389\/fmed.2021.677920.","journal-title":"Front Med (Lausanne)"},{"key":"9419_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.05.024","author":"J Chhatwal","year":"2023","unstructured":"Chhatwal J, Hajjar A, Mueller PP et al. Hepatocellular carcinoma incidence threshold for surveillance in virologically cured hepatitis C individuals. Clin Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.cgh.2023.05.024.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9419_CR36","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.14309\/ajg.0000000000000715","volume":"115","author":"ND Parikh","year":"2020","unstructured":"Parikh ND, Singal AG, Hutton DW, Tapper EB. Cost effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms. Am J Gastroenterol 2020;115:1642\u20131649. https:\/\/doi.org\/10.14309\/ajg.0000000000000715.","journal-title":"Am J Gastroenterol"},{"key":"9419_CR37","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/13696998.2022.2110353","volume":"25","author":"M Blankenburg","year":"2022","unstructured":"Blankenburg M, Elhamamy M, Zhang D et al. Evaluation of the health economic impact of initial diagnostic modality selection in patients suspected of having HCC in China and the USA. J Med Econ 2022;25:1015\u20131029. https:\/\/doi.org\/10.1080\/13696998.2022.2110353.","journal-title":"J Med Econ"},{"key":"9419_CR38","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","volume":"75","author":"GN Ioannou","year":"2021","unstructured":"Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol 2021;75:1476\u20131484. https:\/\/doi.org\/10.1016\/j.jhep.2021.08.012.","journal-title":"J Hepatol"},{"key":"9419_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cgh.2020.09.036","volume":"20","author":"AG Singal","year":"2022","unstructured":"Singal AG, Lok AS, Feng Z, Kanwal F, Parikh ND. Conceptual model for the hepatocellular carcinoma screening continuum: current status and research agenda. Clin Gastroenterol Hepatol 2022;20:9\u201318. https:\/\/doi.org\/10.1016\/j.cgh.2020.09.036.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9419_CR40","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3760\/cma.j.issn.0254-6450.2017.07.005","volume":"38","author":"QS Ma","year":"2017","unstructured":"Ma QS, Liang S, Xiao HW et al. Survey of economic burden of hepatitis B-related diseases in 12 areas in China. Zhonghua Liu Xing Bing Xue Za Zhi 2017;38:868\u2013876. https:\/\/doi.org\/10.3760\/cma.j.issn.0254-6450.2017.07.005.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"9419_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1472-6963-13-37","volume":"13","author":"J Lu","year":"2013","unstructured":"Lu J, Xu A, Wang J et al. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong. China. BMC Health Serv Res 2013;13:37. https:\/\/doi.org\/10.1186\/1472-6963-13-37.","journal-title":"China. BMC Health Serv Res"},{"key":"9419_CR42","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12885-018-4308-7","volume":"18","author":"S Chen","year":"2018","unstructured":"Chen S, Peng Z, Wei M et al. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis. BMC Cancer 2018;18:392. https:\/\/doi.org\/10.1186\/s12885-018-4308-7.","journal-title":"BMC Cancer"},{"key":"9419_CR43","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221140662","author":"K-X Sun","year":"2022","unstructured":"Sun K-X, Cao S-S, Shi F-H et al. First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States. Therapeut Adv Gastroenterol. 2022. https:\/\/doi.org\/10.1177\/17562848221140662.","journal-title":"Therapeut Adv Gastroenterol"},{"key":"9419_CR44","doi-asserted-by":"publisher","first-page":"17139","DOI":"10.1038\/s41598-022-21470-3","volume":"12","author":"H Sugimori","year":"2022","unstructured":"Sugimori H, Hirao M, Igarashi A et al. Health state utilities of patients with hepatitis B and C and hepatitis-related conditions in Japan. Sci Rep 2022;12:17139. https:\/\/doi.org\/10.1038\/s41598-022-21470-3.","journal-title":"Sci Rep"},{"key":"9419_CR45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng A-L, Kokudo N et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317\u2013370. https:\/\/doi.org\/10.1007\/s12072-017-9799-9.","journal-title":"Hepatol Int"},{"key":"9419_CR46","doi-asserted-by":"publisher","unstructured":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance\u2014Terrault\u20142018\u2014Hepatology\u2014Wiley Online Library n.d. https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1002\/hep.29800 (accessed October 4, 2024).","DOI":"10.1002\/hep.29800"},{"key":"9419_CR47","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/healthcare11060824","volume":"11","author":"M Zeng","year":"2023","unstructured":"Zeng M, Li H, Song X, Jiang J, Chen Y. Factors associated with willingness toward organ donation in China: a nationwide cross-sectional analysis using a social-ecological framework. Healthcare (Basel) 2023;11:824. https:\/\/doi.org\/10.3390\/healthcare11060824.","journal-title":"Healthcare (Basel)"},{"key":"9419_CR48","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/lt.24069","volume":"21","author":"J Huang","year":"2015","unstructured":"Huang J, Millis JM, Mao Y, Millis MA, Sang X, Zhong S. Voluntary organ donation system adapted to Chinese cultural values and social reality. Liver Transpl 2015;21:419\u2013422. https:\/\/doi.org\/10.1002\/lt.24069.","journal-title":"Liver Transpl"},{"key":"9419_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40273-012-0011-8","volume":"31","author":"MJ Al","year":"2013","unstructured":"Al MJ. Cost-Effectiveness acceptability curves revisited. PharmacoEconomics 2013;31:93\u2013100. https:\/\/doi.org\/10.1007\/s40273-012-0011-8.","journal-title":"PharmacoEconomics"},{"key":"9419_CR50","unstructured":"Liu Y. Outline of the Healthy China 2030 Plan. n.d. https:\/\/www.gov.cn\/zhengce\/2016-10\/25\/content_5124174.htm (accessed September 22, 2024)."},{"key":"9419_CR51","unstructured":"2018 Korean Liver Cancer Association\u2013National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma\u2014PMC. n.d. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6609431\/ (accessed September 19, 2024)."},{"key":"9419_CR52","doi-asserted-by":"publisher","unstructured":"China guideline for liver cancer screening (2022, Beijing) n.d. https:\/\/www.lcgdbzz.com\/en\/article\/doi\/https:\/\/doi.org\/10.3969\/j.issn.1001-5256.2022.08.007 (accessed September 19, 2024).","DOI":"10.3969\/j.issn.1001-5256.2022.08.007"},{"key":"9419_CR53","first-page":"s4","volume":"13","author":"N M\u00e9ndez-S\u00e1nchez","year":"2014","unstructured":"M\u00e9ndez-S\u00e1nchez N, Paran\u00e1 R, Cheinquer H et al. Latin American Association for the Study of the Liver recommendations on treatment of hepatitis C. Ann Hepatol 2014;13:s4-66.","journal-title":"Ann Hepatol"},{"key":"9419_CR54","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5009\/gnl230089","volume":"18","author":"P Decharatanachart","year":"2024","unstructured":"Decharatanachart P, Pan-Ngum W, Peeraphatdit T et al. Cost-utility analysis of non-contrast abbreviated magnetic resonance imaging for hepatocellular carcinoma surveillance in cirrhosis. Gut Liver 2024;18:135\u2013146. https:\/\/doi.org\/10.5009\/gnl230089.","journal-title":"Gut Liver"},{"key":"9419_CR55","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/hep.30330","volume":"69","author":"HL Kim","year":"2019","unstructured":"Kim HL, An J, Park JA, Park SH, Lim YS, Lee EK. Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis. Hepatology 2019;69:1599\u20131613. https:\/\/doi.org\/10.1002\/hep.30330.","journal-title":"Hepatology"},{"key":"9419_CR56","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/sj.bjc.6604301","volume":"98","author":"J ThomsonCoon","year":"2008","unstructured":"ThomsonCoon J, Rogers G, Hewson P et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 2008;98:1166\u20131175. https:\/\/doi.org\/10.1038\/sj.bjc.6604301.","journal-title":"Br J Cancer"},{"key":"9419_CR57","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0146","author":"Y Nam","year":"2024","unstructured":"Nam Y, Garay OU, Lu X et al. Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost-effectiveness analysis. J Compar Effect Res. 2024. https:\/\/doi.org\/10.57264\/cer-2023-0146.","journal-title":"J Compar Effect Res"},{"key":"9419_CR58","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12913-023-09360-4","volume":"23","author":"ALT Nguyen","year":"2023","unstructured":"Nguyen ALT, Si L, Lubel JS et al. Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study. BMC Health Serv Res 2023;23:378. https:\/\/doi.org\/10.1186\/s12913-023-09360-4.","journal-title":"BMC Health Serv Res"},{"key":"9419_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta11340","volume":"11","author":"J ThomsonCoon","year":"2007","unstructured":"ThomsonCoon J, Rogers G, Hewson P et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007;11:1\u2013206. https:\/\/doi.org\/10.3310\/hta11340.","journal-title":"Health Technol Assess"},{"key":"9419_CR60","doi-asserted-by":"publisher","first-page":"8993","DOI":"10.7314\/apjcp.2014.15.20.8993","volume":"15","author":"P Sangmala","year":"2014","unstructured":"Sangmala P, Chaikledkaew U, Tanwandee T, Pongchareonsuk P. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients. Asian Pacific J Cancer Prev 2014;15:8993\u20139004. https:\/\/doi.org\/10.7314\/apjcp.2014.15.20.8993.","journal-title":"Asian Pacific J Cancer Prev"},{"key":"9419_CR61","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1365-2753.2010.01432.x","volume":"17","author":"Y Chang","year":"2011","unstructured":"Chang Y, Lairson DR, Chan W, Lu S-N, Aoki N. Cost-effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk. J Eval Clin Pract 2011;17:261\u2013267. https:\/\/doi.org\/10.1111\/j.1365-2753.2010.01432.x.","journal-title":"J Eval Clin Pract"},{"key":"9419_CR62","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1038\/ctg.2017.26","volume":"8","author":"N Goossens","year":"2017","unstructured":"Goossens N, Singal AG, King LY et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol 2017;8:e101. https:\/\/doi.org\/10.1038\/ctg.2017.26.","journal-title":"Clin Transl Gastroenterol"},{"key":"9419_CR63","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2016.11.004","volume":"30","author":"S Nakagawa","year":"2016","unstructured":"Nakagawa S, Wei L, Song WM et al. Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition. Cancer Cell 2016;30:879\u2013890. https:\/\/doi.org\/10.1016\/j.ccell.2016.11.004.","journal-title":"Cancer Cell"},{"key":"9419_CR64","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1053\/j.gastro.2013.01.021","volume":"144","author":"Y Hoshida","year":"2013","unstructured":"Hoshida Y, Villanueva A, Sangiovanni A et al. Prognostic gene expression signature for patients with hepatitis c-related early-stage cirrhosis. Gastroenterology 2013;144:1024\u20131030. https:\/\/doi.org\/10.1053\/j.gastro.2013.01.021.","journal-title":"Gastroenterology"},{"key":"9419_CR65","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/gutjnl-2014-307862","volume":"64","author":"LY King","year":"2015","unstructured":"King LY, Canasto-Chibuque C, Johnson KB et al. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut 2015;64:1296\u20131302. https:\/\/doi.org\/10.1136\/gutjnl-2014-307862.","journal-title":"Gut"},{"key":"9419_CR66","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1053\/j.gastro.2011.03.045","volume":"141","author":"BK Abu Dayyeh","year":"2011","unstructured":"Abu Dayyeh BK, Yang M, Fuchs BC et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011;141:141\u2013149. https:\/\/doi.org\/10.1053\/j.gastro.2011.03.045.","journal-title":"Gastroenterology"},{"key":"9419_CR67","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/HEP.0000000000000528","volume":"79","author":"M Narasimman","year":"2024","unstructured":"Narasimman M, Hernaez R, Cerda V et al. Hepatocellular carcinoma surveillance may be associated with potential psychological harms in patients with cirrhosis. Hepatology 2024;79:107. https:\/\/doi.org\/10.1097\/HEP.0000000000000528.","journal-title":"Hepatology"},{"key":"9419_CR68","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/hep4.1823","volume":"5","author":"N Adeniji","year":"2021","unstructured":"Adeniji N, Dhanasekaran R. Current and emerging tools for hepatocellular carcinoma surveillance. Hepatol Commun 2021;5:1972\u20137986. https:\/\/doi.org\/10.1002\/hep4.1823.","journal-title":"Hepatol Commun"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09419-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09419-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09419-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:10:42Z","timestamp":1773292242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09419-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["9419"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09419-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}